Welcome to Glpharma.com


Great Lakes Pharmaceuticals, Inc. is a clinical stage company focused on development and commercialization of products designed to prevent infections associated with indwelling catheters.



Our first product, B-Lock™, is an anti-coagulant catheter lock solution with strong, broad spectrum activity against bacterial and fungal microorganisms known to form biofilm structures in indwelling catheters. Clinical testing of B-Lock™ is planned to start in the fourth quarter of 2008.




Headquartered in Cleveland, OH, Great Lakes Pharmaceuticals assembled team of experienced and distinguished scientists, clinicians and managers to assure development leading to commercialization of innovative, effective product for prevention of catheter related microbial infections in clinical and in outpatient settings.



Great Lakes Pharmaceuticals obtained funding in the amount of $ 2 million from Ohio based entities: JumpStart, Case Technology Ventures, and angel fund groups led by North Coast Anngel Fund. The company also expects to receive a substantial NIH SBIR grant designated for financing of clinical trials of B-Lock™.